-
公开(公告)号：US20240299574A1
公开(公告)日：2024-09-12
申请号：US18672871
申请日：2024-05-23
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph A. D'Alessio , Tony Fleming , Vivek Rauniyar , Eusebio Manchado Robles
IPC: A61K47/68 , A61K31/4745 , A61K45/06 , A61P35/00 , C07K16/18
CPC classification number: A61K47/6803 , A61K31/4745 , A61P35/00 , C07K16/18 , A61K45/06
Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
公开(公告)号：US20150150873A1
公开(公告)日：2015-06-04
申请号：US14620649
申请日：2015-02-12
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph E. Drumm III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: A61K31/506 , A61K31/4545 , A61K31/4439 , A61K31/444
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Abstract translation: 本发明提供式（A）化合物：如本文所述，及其药学上可接受的盐，对映异构体，旋转异构体，互变异构体或外消旋体。 还提供了使用式I化合物治疗PIM激酶介导的疾病或病症的方法和包含这些化合物的药物组合物。
-
公开(公告)号：US12171839B2
公开(公告)日：2024-12-24
申请号：US17833077
申请日：2022-06-06
Applicant: Novartis AG
Inventor： Anthony Edward Boitano , Matthew Burger , Susan E. Cellitti , Michael P. Cooke , Catrin Finner , Bernhard Hubert Geierstanger , Yunho Jin , Si Tuen Lee-Hoeflich , HongNgoc Thi Pham , Siew Ho Schleyer , Kathrin Tissot , Tetsuo Uno , Ben Wen
Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
-
公开(公告)号：US09242969B2
公开(公告)日：2016-01-26
申请号：US14204823
申请日：2014-03-11
Applicant: Novartis AG
Inventor： Paul A. Barsanti , Matthew Burger , Yan Lou , Gisele Nishiguchi , Valery Polyakov , Savithri Ramurthy , Alice Rico , Lina Setti , Aaron Smith , Benjamin Taft , Huw Tanner , Alan DiPesa , Naeem Yusuff
IPC: C07D401/04 , C07D403/04 , A61K31/5377 , A61K31/541 , C07D413/04 , A61K45/06 , C07D213/74 , C07D237/20 , C07D239/42 , C07D239/47 , C07D239/48 , C07D277/42 , C07D401/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D493/10 , C07D403/12 , C07D401/14 , C07D405/14 , C07D213/75 , C07D233/88 , C07D405/04 , C07D405/12 , C07D241/20 , C07D471/04 , C07D487/04 , C07D263/58 , C07D491/107 , C07D493/04 , C07D495/04 , C07D498/08 , C07D513/04
CPC classification number: A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
Abstract translation: 本发明提供了本文所述的式（I）化合物及其盐，以及这些化合物治疗与Raf激酶活性相关的疾病的治疗用途。 本发明还提供包含这些化合物的药物组合物，以及包含这些化合物和治疗性助剂的组合物。
-
公开(公告)号：US08987457B2
公开(公告)日：2015-03-24
申请号：US13897927
申请日：2013-05-20
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph E. Drumm, III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: C07D211/68 , C07D213/44 , C07D417/00 , A61K31/445 , A61K31/41 , C07D213/81 , C07D403/12 , C07D401/14 , C07D401/12 , C07D403/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/675 , A61K45/06 , C07D405/14 , C07F9/6558
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
-
Patent Agency Ranking
公开(公告)号：US20240189439A1
公开(公告)日：2024-06-13
申请号：US18454457
申请日：2023-08-23
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph Anthony D'Alessio , Tony Fleming , Vivek Rauniyar , Eusebio Manchado Robles , Christian Kunz , Markus Waldhuber
IPC: A61K47/68 , A61K31/4745 , A61P35/00 , C07K16/18
CPC classification number: A61K47/6803 , A61K31/4745 , A61P35/00 , C07K16/18 , A61K45/06
Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates of said antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention also relates to methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
公开(公告)号：US20150133473A1
公开(公告)日：2015-05-14
申请号：US14402541
申请日：2013-05-20
Applicant: NOVARTIS AG
Inventor： Matthew Burger , Joseph E. Drumm III , Gisele Nishiguchi , Alice Rico , Robert Lowell Simmons , Benjamin Taft , Huw Tanner
IPC: C07D417/14 , C07D417/12 , C07D409/14 , C07D405/14 , C07D401/14 , C07D401/12
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/675 , A61K45/06 , C07D213/81 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/14 , C07D407/14 , C07D409/14 , C07D417/12 , C07D417/14 , C07F9/65583
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
-
公开(公告)号：US20250064964A1
公开(公告)日：2025-02-27
申请号：US18937914
申请日：2024-11-05
Applicant: Novartis AG
Inventor： Anthony Edward Boitano , Matthew Burger , Susan E. Cellitti , Michael P. Cooke , Catrin Finner , Bernhard Hubert Geierstanger , Yunho Jin , Si Tuen Lee-Hoeflich , HongNgoc Thi Pham , Siew Ho Schleyer , Kathrin Tissot , Tetsuo Uno , Ben Wen
Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoetic stem cells in a patient in need thereof.
-
公开(公告)号：US11779649B2
公开(公告)日：2023-10-10
申请号：US16718866
申请日：2019-12-18
Applicant: Novartis AG
Inventor： Matthew Burger , Joseph Anthony D'Alessio , Tony Fleming , Vivek Rauniyar , Eusebio Manchado Robles , Christian Kunz , Markus Waldhuber
IPC: A61K47/68 , A61P35/00 , A61K31/4745 , C07K16/18 , A61K45/06
CPC classification number: A61K47/6803 , A61K31/4745 , A61P35/00 , C07K16/18 , A61K45/06
Abstract: This application discloses anti-PMEL17 antibodies, antigen binding fragments thereof, and antibody drug conjugates comprising antibodies or antigen binding fragments conjugated to a GNAQ/GNA11 inhibitor. The application also discloses methods of treating or preventing cancer using the antibodies, antigen binding fragments, and antibody drug conjugates. Also disclosed herein are methods of making the antibodies, antigen binding fragments, and antibody drug conjugates, and methods of using the antibodies and antigen binding fragments as diagnostic reagents.
-
公开(公告)号：US11357864B2
公开(公告)日：2022-06-14
申请号：US16470897
申请日：2017-12-19
Applicant: NOVARTIS AG
Inventor： Ben Wen , Anthony E. Boitano , Matthew Burger , Susan E. Cellitti , Michael P. Cooke , Catrin Finner , Bernhard Hubert Geierstanger , Yunho Jin , Si Tuen Lee-Hoeflich , HongNgoc Thi Pham , Siew Ho Schleyer , Kathrin Tissot , Tetsuo Uno
Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.02 seconds)
